Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

19 Jan 2005 07:00

Embargoed Release: 07:00hrs Wednesday 19 January 2005 SOPHEON PLC (`Sopheon') Atrium Medical Center Selects Sopheon's Accolade Solution to Manage Clinical Trials and Innovation Projects Software Will Support Compliance with New European-Union Clinical Trial Regulations and Help Ensure Projects Are Executed Efficiently and On Time Sopheon, the international provider of solutions that improve the return frominnovation and product development, announces that Atrium Medical Center, oneof the largest general hospitals in the Netherlands, is deploying Sopheon'sAccolade solution to support implementation of a structured process forcomprehensive management of clinical trials. Use of the software is expected tohelp Atrium enhance management of trials activity and ensure compliance withthe latest European Union (EU) clinical research regulations. Accolade willalso be used by the hospital to manage innovation projects, including majorcapital investment initiatives."Pharmaceutical companies judge our clinical-trial work by the quality of theresults and the speed and cost-effectiveness with which those results aredelivered," said Dr. Graham Ramsay of Atrium's board. "Patients depend upon ourability to effect the right kinds of innovation and make the right capitalinvestments to ensure that they receive the best available care. Sopheon'ssoftware will integrate our processes for managing clinical trials andinnovation projects, making those processes more stable, predictable andefficient."The hospital is deploying Accolade at its facilities in Heerlen, Kerkrade andBrunssum. Atrium conducts approximately 70 clinical trials per year for leadingpharmaceutical companies. It is anticipated that use of the software system,which will eventually handle as many as 240 trials at one time, will increaseclinical-trials revenue by enabling faster trial preparation and execution,higher quality results and improved service to clients. Sopheon also workedclosely with Atrium to configure Accolade to fit a new, jointly-developedprocess incorporating elements of the Six Sigma manufacturing methodology thatwill be applied to management of innovation initiatives.Accolade will replace the manual, paper-based process structure that Atriumpreviously used to manage clinical trials with a reliable, easy-to-useWeb-based framework for everything from tracking schedules and budgets toassessing and allocating resources, conducting financial analyses and examiningtrial results. The system provides hospital executives, managers, clinicaltrial coordinators, doctors and researchers with the information supportrequired for tactical, day-to-day management activity as well as for strategic,longer-term business decision-making. Atrium plans to extend access to thesystem to pharmaceutical clients interested in checking on the status of trialprojects involving their products.Sopheon's CEO Andy Michuda said:"Clinical trial management is a critical step in the cycle that movespharmaceutical products from conception and development to safe adoption in themarketplace. It's estimated that, in the United States alone, approximately80,000 clinical trials are being conducted at any one time. The scale ofopportunity associated with effecting improvements in this area is great.Accolade's capacity to reduce the expense and inefficiency of the clinicaltrial process has led to its adoption by some of the leading clinical hospitalsin the world. Atrium is one such leader, and a prime example of how forwardthinking healthcare providers are harnessing technology to benefit stakeholdersthroughout the value chain."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Barbara Jansen Citigate First Financial Tel : + 31 (0) 205 754 010About Atrium Medical CenterWith 3600 employees and 1230 beds, Atrium Medical Center (Atrium) is one of thelargest employers in the south of the Netherlands. In 2004 Atrium celebratedits 100-year anniversary. It has a national reputation for hospital innovation,and has recently participated in experimental studies on reducing patientwait-lists, increasing care-delivery production, implementing new budgetarysystems and improving patient safety. In 2003, supported by a ¢â€š¬187 millionbudget, Atrium registered 28,000 clinical admissions, 24,000 day admissions and432,000 patient visits to its policlinics. Atrium's focus on patients,professionalism, and continuity and effectiveness of treatment ensures that thequality of care it provides remains on the highest levels.About SopheonSopheon (LSE: SPE) is an international provider of software and services. TheSopheon Accolade product development system automates gate- or phase-basedproduct development processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time-to-market. Sopheon's Monitor software operates as a "readingrobot" that automatically reviews, filters, analyzes and pushes relevantcontent to healthcare and engineering professionals to enable effectivecompliance with protocols, standards and regulations. Sopheon is listed on theAIM Market of the London Stock Exchange and on the Euronext in the Netherlands.For more information, please visit www.sopheon.com.END
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.